INTRODUÇÃO: Acidente vascular cerebral (AVC), depressão e prejuízo cognitivo são comorbidades associadas à alta carga mundial de incapacidade. Depressão e prejuízo cognitivo são condições que ocorrem mais frequentemente em pacientes pós-AVC e estão associadas a um aumento da morbimortalidade. OBJETIVO: Investigar potenciais fatores de risco cerebrovasculares associados ao desenvolvimento de depressão pós-AVC (DPA) e prejuízo cognitivo pós-AVC (PC) com base na neuroimagem por ressonância magnética cerebral (RM) e biomarcadores (serotonina, BDNF, IL-6, IL-18) na fase subaguda (1-3 meses) e na fase crônica (até 2 anos de seguimento) após o AVC em sobreviventes do Estudo de Mortalidade e Morbidade do AVC (EMMA), São Paulo, Brasil. MÉTODOS: Amostra de participantes admitidos por AVC no Departamento de Emergências do HU-USP, de abril de 2006 a novembro de 2014, foi submetida a avaliações clínicas e neurológicas. Os principais instrumentos para avaliação de depressão foram: Entrevista Clínica Estruturada para DSM-4 eixo 1 (SCID-I) e Questionário de Saúde do Paciente - versão 9 itens (PHQ-9); e para comprometimento cognitivo: Entrevista Telefônica Modificada para Estado Cognitivo (TICS-M), aplicados em 1-3 meses, 6 meses e anualmente até 2 anos. Além da quantificaçao da DPA e PC e fatores associados em 1-3 meses (fase subaguda), na fase crônica foram realizadas análises de sobrevida pelas curvas de Kaplan-Meier e modelos de regressão logística de Cox (Razão de Risco - RR, interval de confiança- IC95%) para investigar a progressão de DPA ou PC aos 6 meses e 2 anos, de acordo com lateralidade do AVC. RESULTADOS: Dos 103 pacientes elegíveis, 85,4% apresentaram AVC isquêmico e 73,7% foram diagnosticados como primeiro evento. Na fase subaguda, 27,2% apresentaram PC e 13,6% apresentaram DPA (5,8% com \"primeiro episódio\" e 7,8% com depressão \"recorrente\"). DPA e/ou PC foram associados com baixa escolaridade, gênero feminino e idade entre 55 e 74 anos. Em 1-3 meses pós-AVC, a lesão cerebral do hemisfério esquerdo foi mais frequentemente associada ao aumento do PC do que à lesão à direita (71,4% vs. 28,4%, p = 0,005). A DPA não esteve associada à lateralidade do AVC. No geral, os níveis de biomarcadores não apresentaram alterações nos pacientes XX com DPA e PC. No seguimento até 2 anos, foi encontrada uma frequência de 19% de DPA e 38% de PC. A maioria dos participantes (53%) apresentou AVC no hemisfério direito, entretanto o AVC neste hemisfério não esteve associado com DPA ou PC. Confirmando os dados observados em 1-3 meses pós-evento, o AVC do lado esquerdo foi um preditor independente de PC em longo prazo, mas não de DPA. O AVC esquerdo foi associado a uma alta probabilidade de PC (42,6% e 53,2%, respectivamente, aos 6 meses e 2 anos, p-log-rank: 0,002). A RR de PC por AVC à esquerda foi de 3,38 (IC95%, 1,35-8,50) aos 6 meses e foi mantida aos 2 anos (RR 3,38; IC95%, 1,50-7,59). CONCLUSÕES: PC associou-se a uma menor escolaridade, sexo feminino e faixa etária entre 55 a 74 anos. O AVC no hemisfério esquerdo esteve associado a uma maior frequência de PC, apresentando um risco 3 vezes maior para o desenvolvimento de PC ao longo de 2 anos após o AVC / INTRODUCTION: Stroke, depression and cognitive impaiment are comorbidities associated with the high burden of disability worldwide. Depression and cognitive impairment are responsible for increased post-stroke morbidity and mortality. OBJECTIVE: To investigate the cerebrovascular risk factors associated with the development of post-stroke depression (PSD) and post-stroke cognitive impairment (PCI) based on brain magnetic resonance imaging (MRI) and biomarkers (serotonin, BDNF, IL-6, IL-18) in the subacute phase (1-3 months) and in the chronic phase (up to 2 years of follow-up) after stroke in survivors of the Stroke Mortality and Morbidity Study (EMMA), São Paulo, Brazil. METHODS: Stroke participants prospectively admitted at HU-USP Emergency Department from April 2006 to November 2014 underwent clinical and neurological evaluations. The main instruments for evaluation of depression were: Structured Clinical Interview for DSM-4 axis 1 (SCID-I) and Patient Health Questionnaire version 9 items (PHQ-9); and cognitive impairment: Modified Telephone Interview for Cognitive Status (TICS-M), applied in 1-3 months, 6 months and annually up to 2 years. In addition of the quantification of PSD and PCI and associated factors in 1-3 months (subacute phase), survival analyzes were performed on Kaplan-Meier curves and Cox logistic regression models (Hazard Ratio-HR, confidence interval-95% CI) to investigate the progression of PSD or PCI at 6 months and 2 years, according to laterality of the stroke. RESULTS: Of the 103 eligible patients, 85.4% had ischemic stroke and 73.7% had a stroke for the first time. In the subacute phase, 27.2% had PCI and 13.6% had current PSD (5.8% with \"first episode\" and 7.8% with \"recurrent\" depression). PSD and / or PCI were associated with low educational level, female gender and 55-74 years old. In 1-3 months, left-sided stroke was more frequently associated with an increase in PCI than right lesion (71.4% vs. 28.4%, p = 0.005). PSD was not associated with laterality of the stroke. Overall, biomarkers levels did not show changes in patients with PSD and PCI. Up to 2 years follow-up, it was found a frequency of 19% of DPA and 38% of PCI. Most participants (53%) presented right-sided stroke, however, it was not associated with PSD or PCI. Confirming the observed data at 1-3 months post-event, left-sided stroke XXI I was an independent predictor of long-term PCI but not PSD. Left-sided stroke was associated with a high probability of PCI (42.6% and 53.2%, respectively at 6 months and 2 years, p-log rank: 0.002). The risk ratio (RR) of PCI due to left-sided stroke was 3.38 (95% CI, 1.35-8.50) at 6 months and maintained at 2 years (RR 3.38, 95% CI, 1, 50-7.59). CONCLUSIONS: PCI was associated with lower educational level, female gender and age group between 55 and 74 years. Stroke in the left hemisphere was associated with a higher frequency of PCI and the risk of developing cognitive impairment over 2 years after stroke was 3

INTRODUÇÃO: Acidente vascular cerebral (AVC), depressão e prejuízo cognitivo são comorbidades associadas à alta carga mundial de incapacidade. Depressão e prejuízo cognitivo são condições que ocorrem mais frequentemente em pacientes pós-AVC e estão associadas a um aumento da morbimortalidade. OBJETIVO: Investigar potenciais fatores de risco cerebrovasculares associados ao desenvolvimento de depressão pós-AVC (DPA) e prejuízo cognitivo pós-AVC (PC) com base na neuroimagem por ressonância magnética cerebral (RM) e biomarcadores (serotonina, BDNF, IL-6, IL-18) na fase subaguda (1-3 meses) e na fase crônica (até 2 anos de seguimento) após o AVC em sobreviventes do Estudo de Mortalidade e Morbidade do AVC (EMMA), São Paulo, Brasil. MÉTODOS: Amostra de participantes admitidos por AVC no Departamento de Emergências do HU-USP, de abril de 2006 a novembro de 2014, foi submetida a avaliações clínicas e neurológicas. Os principais instrumentos para avaliação de depressão foram: Entrevista Clínica Estruturada para DSM-4 eixo 1 (SCID-I) e Questionário de Saúde do Paciente - versão 9 itens (PHQ-9); e para comprometimento cognitivo: Entrevista Telefônica Modificada para Estado Cognitivo (TICS-M), aplicados em 1-3 meses, 6 meses e anualmente até 2 anos. Além da quantificaçao da DPA e PC e fatores associados em 1-3 meses (fase subaguda), na fase crônica foram realizadas análises de sobrevida pelas curvas de Kaplan-Meier e modelos de regressão logística de Cox (Razão de Risco - RR, interval de confiança- IC95%) para investigar a progressão de DPA ou PC aos 6 meses e 2 anos, de acordo com lateralidade do AVC. RESULTADOS: Dos 103 pacientes elegíveis, 85,4% apresentaram AVC isquêmico e 73,7% foram diagnosticados como primeiro evento. Na fase subaguda, 27,2% apresentaram PC e 13,6% apresentaram DPA (5,8% com \"primeiro episódio\" e 7,8% com depressão \"recorrente\"). DPA e/ou PC foram associados com baixa escolaridade, gênero feminino e idade entre 55 e 74 anos. Em 1-3 meses pós-AVC, a lesão cerebral do hemisfério esquerdo foi mais frequentemente associada ao aumento do PC do que à lesão à direita (71,4% vs. 28,4%, p = 0,005). A DPA não esteve associada à lateralidade do AVC. No geral, os níveis de biomarcadores não apresentaram alterações nos pacientes XX com DPA e PC. No seguimento até 2 anos, foi encontrada uma frequência de 19% de DPA e 38% de PC. A maioria dos participantes (53%) apresentou AVC no hemisfério direito, entretanto o AVC neste hemisfério não esteve associado com DPA ou PC. Confirmando os dados observados em 1-3 meses pós-evento, o AVC do lado esquerdo foi um preditor independente de PC em longo prazo, mas não de DPA. O AVC esquerdo foi associado a uma alta probabilidade de PC (42,6% e 53,2%, respectivamente, aos 6 meses e 2 anos, p-log-rank: 0,002). A RR de PC por AVC à esquerda foi de 3,38 (IC95%, 1,35-8,50) aos 6 meses e foi mantida aos 2 anos (RR 3,38; IC95%, 1,50-7,59). CONCLUSÕES: PC associou-se a uma menor escolaridade, sexo feminino e faixa etária entre 55 a 74 anos. O AVC no hemisfério esquerdo esteve associado a uma maior frequência de PC, apresentando um risco 3 vezes maior para o desenvolvimento de PC ao longo de 2 anos após o AVC / INTRODUCTION: Stroke, depression and cognitive impaiment are comorbidities associated with the high burden of disability worldwide. Depression and cognitive impairment are responsible for increased post-stroke morbidity and mortality. OBJECTIVE: To investigate the cerebrovascular risk factors associated with the development of post-stroke depression (PSD) and post-stroke cognitive impairment (PCI) based on brain magnetic resonance imaging (MRI) and biomarkers (serotonin, BDNF, IL-6, IL-18) in the subacute phase (1-3 months) and in the chronic phase (up to 2 years of follow-up) after stroke in survivors of the Stroke Mortality and Morbidity Study (EMMA), São Paulo, Brazil. METHODS: Stroke participants prospectively admitted at HU-USP Emergency Department from April 2006 to November 2014 underwent clinical and neurological evaluations. The main instruments for evaluation of depression were: Structured Clinical Interview for DSM-4 axis 1 (SCID-I) and Patient Health Questionnaire version 9 items (PHQ-9); and cognitive impairment: Modified Telephone Interview for Cognitive Status (TICS-M), applied in 1-3 months, 6 months and annually up to 2 years. In addition of the quantification of PSD and PCI and associated factors in 1-3 months (subacute phase), survival analyzes were performed on Kaplan-Meier curves and Cox logistic regression models (Hazard Ratio-HR, confidence interval-95% CI) to investigate the progression of PSD or PCI at 6 months and 2 years, according to laterality of the stroke. RESULTS: Of the 103 eligible patients, 85.4% had ischemic stroke and 73.7% had a stroke for the first time. In the subacute phase, 27.2% had PCI and 13.6% had current PSD (5.8% with \"first episode\" and 7.8% with \"recurrent\" depression). PSD and / or PCI were associated with low educational level, female gender and 55-74 years old. In 1-3 months, left-sided stroke was more frequently associated with an increase in PCI than right lesion (71.4% vs. 28.4%, p = 0.005). PSD was not associated with laterality of the stroke. Overall, biomarkers levels did not show changes in patients with PSD and PCI. Up to 2 years follow-up, it was found a frequency of 19% of DPA and 38% of PCI. Most participants (53%) presented right-sided stroke, however, it was not associated with PSD or PCI. Confirming the observed data at 1-3 months post-event, left-sided stroke XXI I was an independent predictor of long-term PCI but not PSD. Left-sided stroke was associated with a high probability of PCI (42.6% and 53.2%, respectively at 6 months and 2 years, p-log rank: 0.002). The risk ratio (RR) of PCI due to left-sided stroke was 3.38 (95% CI, 1.35-8.50) at 6 months and maintained at 2 years (RR 3.38, 95% CI, 1, 50-7.59). CONCLUSIONS: PCI was associated with lower educational level, female gender and age group between 55 and 74 years. Stroke in the left hemisphere was associated with a higher frequency of PCI and the risk of developing cognitive impairment over 2 years after stroke was 3

Made available in DSpace on 2016-01-26T12:51:35Z (GMT). No. of bitstreams: 1 helenicebianchibolini_tese.pdf: 2235516 bytes, checksum: 0e1ddb1957f1b10e0d67a793c7e4a245 (MD5) Previous issue date: 2010-10-27 / The practical problem observed referred to the clinical symptoms of NF1, involving intellectual performance and psychosocial characteristics of their carriers. This sends us to the NF1-intelligence interface. Objective: To identify and compare indices of intelligence and their frequencies in patients with NF1, attended at CEPAN. Methods and Casuistry: Medical records were used in research, semi-structured interview, the Wechsler Scales and Test Progressive Matrices Scale-General. Were applied indidually, to the 77 subjects, of which 30 patients with NF1, 17 family members, and 30 non- carriers between 2006 and 2010. The data were treated qualitative-quantitative. Results: The socioeconomic and cultural rights did not differ between subjects. Minors (<20 ) and larger (>20 ) time spent in the execution of Test Progressive Matrices Sacale-General were relatives of patients with NF1 and most were using medication. Mean correct responses were lower in patients with NF1, they had one and two symptoms that bothered when they were diagnosed, currently, the troubled portability three, four and two symptoms. Patients with NF1 had their first symptoms identified with more than five years age, they had relatives suffering from NF1 1st and/or 2nd degrees of relatedness (vertical transmission). They had mild MR and moderate, and learning disabilities. The subjects of this investigation showed TIQ; VIQ; TIQ/Gc; IOP/Gv; IVP/Gt average and below average; although the ability Reasoning/ Fluid Intelligence Gf category V. Conclusions: The subjects of this investigation have average and average lower, with limited sustainability. There are differences in intellectual performance among them: relatives of patients with NF1 are superior to the carriers and no- carriers are superior to both. There are mental retardation, learning disabilities, difficulties visual-perceptual-motor, memory impairments, and speech in written and spoken language in patients with NF1. There are no correlations between TIQ/Gc; IMO/Gsm; ICV/Gc; IOP/Gv; IVP/Gt and number of symptoms. There is no correlation between IQ, intellectual level, types, numbers, uncomfortable symptoms and age of onset of symptoms. / O problema prático observado, referiu-se aos sintomas clínicos de NF1, que envolviam o desempenho intelectual e as características psicossociais de seu portador, remetendo-nos à interface inteligência Neurofibromatose 1-NF1. Objetivo: Identificar e comparar os índices de inteligência e suas frequências em portadores de NF 1 atendidos no CEPAN. Casuística e Métodos: Utilizou-se pesquisa em prontuários; entrevista semi-estruturada; as Escalas de Wechsler e Testes de Matrizes Progressivas - Escala Geral, aplicados individualmente a 77 sujeitos, dos quais 30 portadores de NF1, 17 seus familiares e 30 não-portadores, entre 2006 e 2010. Os dados receberam tratamento quali-quantitativo. Resultados: As características socioeconômicas e culturais não diferiram entre os sujeitos Os tempos menores (<20 ) e maiores (>20 ) gastos na execução do Raven - Escala Geral foram de familiares e portadores de NF1, que mais faziam uso de medicação. As médias de acertos de portadores de NF1 foram as menores; possuíam 1 e 2 sintomas que os incomodavam quando foram diagnosticados; atualmente, era a portabilidade de 3, 4 e 2 sintomas que os incomodavam; primeiros sintomas identificados com mais de 5 anos; possuíam parentes portadores de NF1 de 1º e/ou 2º graus de parentesco (transmissão vertical); apresentaram RM leve e moderada; e distúrbio de aprendizagem (QI>70) em portadores de NF1. Os sujeitos dessa investigação apresentaram quocientes de inteligência e índices fatoriais médios e médio-inferiores; a capacidade Raciocínio/ Inteligência Fluida Gf encontrou-se comprometida-categoria V. Conclusões: Os sujeitos da investigação possuem inteligência média e média inferior, porém com dificuldade de sustentabilidade. Há diferenças de desempenho intelectual: familiares de portadores de NF1 são superiores aos portadores de NF1; e não portadores são superiores a ambos. Há retardo mental, distúrbio de aprendizagem, disfunção no desenvolvimento da linguagem dificuldades viso-motoras e perceptuais, deficiências de memória e de expressão na linguagem escrita e verbal em portadores de NF1; ausência de correlação entre QIT/Gc; IMO/Gsm; ICV/Gc; IOP/ Gv; IVP/ Gt e número de sintomas; e ausência de relação entre QI; nível intelectual; tipos; números; incômodos de sintomas e faixa etária do aparecimento dos primeiros sintomas.

Personer med intellektuell funktionsnedsättning har svårigheter att förstå och tolka hälsoinformation, och har därmed en ökad risk för att drabbas av livsstilsrelaterade sjukdomar. Syftet med denna studie var att beskriva hur personer med intellektuell funktionsnedsättning upplevde att delta i en hälsoutbildning om fysisk aktivitet och hälsosamma matvanor, samt vilka erfarenheter de fått av utbildningen. Studien baserades på ett pilotprojekt, Hälsan spelar roll. En kvalitativ studiedesign användes och data insamlades vid nio semistrukturerade intervjuer, vilka analyserades med kvalitativ innehållsanalys med induktiv ansats. Resultatet visade att studiedeltagarna var nöjda med utbildningen Hälsan spelar roll och de hade utökat sina kunskaper inom hälsa, kost och träning. De upplevde att de hade blivit mer fysiskt aktiva än tidigare och att de förbättrat sina matvanor efter kursen. Studiedeltagarna upplevde att de hade blivit gladare och såg mer positivt på livet. Det upplevdes även stärkande att delta i grupp, vilket motiverade dem till att göra en förändring, och samtidig kunde kursledarna tillgodose deras individuella stödbehov. Att bibehålla nya vanor upplevdes ibland svårt när hälsosamma vanor inte alltid uppmärksammades hemma. Studiedeltagarna verkar uppleva att hälsoutbildningen Hälsan spelar roll kan förbättra deras levnadsvanor. Dock kan det ibland vara svårt för målgruppen att fortsätta med nya vanor efter avslutad utbildning, om stöd saknas. / People with intellectual disabilities can have difficulty to understand and interpret health information, thus having an increased risk of lifestyle related diseases. The aim of this study was to describe how people with intellectual disabilities experienced the participation in a health education program regarding physical activity and nutrition. The study is based on a pilot project, Hälsan spelar roll. A qualitative study design model was used, and data was collected through semi-structured interviews with nine participants and were analysed with content analysis. The study shows that the participants were satisfied with the program, and had increased their knowledge in health, nutrition, and exercise. During the program, they experienced an increase in physical activity levels and improved their nutritional habits. The participants exhibited a more positive outlook on life. They found it uplifting and motivating to participate in a group program, which encouraged them to change, while concurrently allowing the course leader to address their individual needs. Maintaining new habits, could prove challenging for the participants, if their healthy habits are not supported at home. The participants of the program also seemed to experience improvements in their daily habits through their participation in the health program. However, if support is lacking, the target group can have difficulties maintaining their new habits upon program completion.

Introducció: La Malaltia d’Alzheimer (AD), és la malaltia neurodegenerativa amb més incidència actualment. La hipòtesi més acceptada sobre l’origen de la malaltia és la “hipòtesi amiloide”, en la que el cúmul de pèptid beta amiloide (Aβ) a l’espai extracel•lular a cervell du a la formació d’oligòmers solubles, fibril•les i plaques provocant una disfunció sinàptica i neuronal i, conseqüentment, dèficits cognitius. Tots aquests esdeveniments van acompanyats de neuroinflamació i de la formació de cabdells neurofibril•lars. Diversos són els models animals utilitzats per a l’estudi l’AD, dintre dels quals hi trobem els gossos de companyia envellits s’ha descrit la Síndrome de Disfunció Cognitiva (CDS). Els gossos amb la CDS es caracteritzen per presentar per alteracions a nivell cognitiu, anatòmic i histopatològic similars les descrites anteriorment i comparables a les observades en els estadis inicials de l’AD. Totes aquestes convergències, fan que el gos amb la CDS sigui considerat un bon model natural d’envelliment humà i dels estadis més inicials de l’AD i que pugui ser de gran utilitat en estudis de tractaments dirigits l’AD. Dintre dels tractaments dirigits a la prevenció de la formació i/o eliminació d’amiloide hi trobem les immunoteràpies anti-amiloide actives. Aquestes, mitjançant l’administració d’un fragment d’Aβ sintètic combinat amb diversos adjuvants i proteïnes transportadores, indueix l’eliminació d’amiloide de Sistema Nerviós Central cap a la perifèria mitjançant diversos mecanismes. Des de l’estudi fet l’any 2000 amb la immunoteràpia (AN1792), dissenyada a partir de l’Aβ42 i QS21 com a adjuvant, que va provocar un 6% de casos de meningoencefalitis en els pacients inclosos a l’estudi, diversos han estat els esforços per dissenyar vacunes eficaces i que evitin els efectes secundaris no desitjats. Objectiu general: En aquest treball es planteja si l’administració d’una immunoteràpia dissenyada a partir d’un adjuvant que indueix respostes de tipus Th2 o anti-inflamatòria juntament amb un fragment C-terminal del pèptid Aβ fibril•lar indueix una millora cognitiva en gossos amb CDS, evitant els efectes nocius observats en immunoteràpies ja testades en humans. / Development of an anti-amyloid therapy for Alzheimer Disease in dogs with Cognitive Dysfunction Introduction: Alzheimer’s Disease (AD) is a neurodegenerative disease where the cognitive deficits are due to the accumulation of the different forms of amyloid beta peptide (Aβ) (oligomers, fibrils and plaques). They also induce neuroinflamation and the formation of the neurofibrillary tangles. Aged dogs with Cognitive Dysfunction Syndrome (CDS) also present cognitive deficits associated to the accumulation of the different forms of Aβ into the brain. Because of the similarities with AD, dogs with CDS are considered a good model for the study of aging human and the first stages of AD. Active anti-amyloid immunotherapy is one of the strategies proposed with the aim to ameliorate the cognitive deficits through the clearance of the amyloid burden from the central nervous system to the periphery. After the harmful side effects due to the administration of the immunotherapy AN1792 in the 21st century, studies with different anti-amyloid immunotherapies have been performed with the aim to prevent and/or ameliorate AD and avoiding the side affects. Objective: This work considers the development of an immunotherapy designed with a Th2 adjuvant and C-terminal fragments of the fibrillar Aβ to induce a cognitive improvement in CDS dogs avoiding the side effects of the immunotherapies tested in humans. Results: The immunization study was performed after the selection of the V5 vaccine designed using the mixture of the Aβ1-40 + KLH-Aβy-40 fragments and the Aluminium Hydroxide (Alum®) as the adjuvant. V5 vaccine was administrated during a fifty days period to CDS dogs (n=12) and housed adult beagle dogs (n=9). Changes in cognitive deficits, in biochemistry and haematologist biomarkers were observed during the follow-up period. With the aim to observe the changes in neuroinflamation responses, a comparative study between brain samples form unimmunized and immunized dogs was performed as well. Increases in the Aβplasma/ AβLCR ratio associated to the reduction of the neuroinflamation responses could diminish the neuronal damage leading to a cognitive improvement without side effects in CDS dogs.

Altersassoziiert entwickeln Hunde eine Erkrankung, die in vielen Aspekten der Alzheimer-Krankheit des Menschen ähnelt. Das canine kognitive Dysfunktionssyndrom äußert sich klinisch u.a. durch Desorientierung in vertrauter Umgebung, Vergessen von Kommandos und einen gestörten Schlaf-Wach-Rhythmus. Aus der Literatur ist bekannt, dass in den Gehirnen von alten Hunden regelmäßig Aβ- und selten Tauablagerungen zu beobachten sind. Allerdings erfolgte bisher kein Nachweis des hochgradig zytotoxischen und modifizierten pE3Aβ. Auch Veränderungen der mikroglialen Morphologie wurden bisher nicht beschrieben. Insgesamt lagen in dieser Studie 24 euthanasierte Rasse- und Mischlingshunde verschiedenen Alters vor. Fünf dieser Tiere besaßen ein durchschnittliches Alter von 2,1 Jahren und dienten als Kontrollgruppe. Die anderen 19 Hunde waren 8 bis 19 Jahre alt und wurden entsprechend ihrer Größe und des Gewichts in die drei Kategorien kleine (≤ 10 kg), mittelgroße (10 – 25 kg) und große Hunde (> 25 kg) unterteilt. Die Gehirne wurden aus den Schädeln präpariert und in 4 % Paraformaldehyd fixiert. Anschließend erfolgte die Präparation des frontalen und entorhinalen Kortex sowie der Hippokampusformation, die in 30%iger Saccharoselösung vitrifiziert und mittels Methylbutan bei -80 °C eingefroren wurden. Von den Regionen wurden Kryoschnitte mit einer Dicke von 40 µm angefertigt und diese anhand immunhistologischer Färbungen auf das Vorhandensein von Ablagerungen, bestehend aus den Amyloidsubtypen Aβ8-17 und pE3Aβ, sowie aus hyperphosphorylierten Tau, untersucht. Die Morphologie und das Aktivitätsstadium der Mikroglia wurden mit Antikörpern gegen Iba1 und TAL.1B5 analysiert. Zusätzlich erfolgte eine Untersuchung anhand des Filament Tracer. Stereologische Analysemethoden wurden zur Quantifizierung der Aβ-Ablagerungen und der Mikroglia angewandt. Disseminierte Plaques fanden sich bereits ab 9 Jahren. In den untersuchten Gehirnregionen von alten Hunden zeichnete sich ein progressiver Verlauf der Ablagerungen ab. Da insbesondere kleinere Hunde ein höheres Alter erreichten als mittelgroße und große Hunde konnten in dieser Kategorie vermehrt Plaques beobachtet werden. Den alten Tieren gemein war, dass in den untersuchten Gehirnregionen pE3Aβ-Plaques häufiger vorlagen als Plaques, die aus Aβ8-17 bestanden. Kleinere parenchymale und meningeale Gefäße des frontalen Kortex schienen besonders anfällig gegenüber pE3Aβ-Ablagerungen zu sein. Im entorhinalen Kortex von kleinen Hunden war die Menge an gefäßassoziierten Aβ8-17- und pE3Aβ-Ablagerungen annähernd gleich. Bei mittelgroßen und großen Hunden dominierte im entorhinalen Kortex und ventralen Hippokampus die Anzahl an gefäßassoziierten Aβ8-17-Ablagerungen. Bei kleinen Hunden existierten im ventralen Hippokampus signifikant mehr gefäßassoziierte Aβ8-17- als pE3Aβ-Ablagerungen. Hyperphosphoryliertes Tau fand sich in der Hippokampusformation von drei Hunden im Alter von 11 bzw. 15 Jahren. Der Schweregrad war unterschiedlich ausgeprägt, sodass nur ein Hund eine hochgradige Pathologie mit NFTs und neuritischen Plaques aufwies. Einhergehend mit dem Alter und einer assoziierten Proteinpathologie fanden sich Veränderungen der mikroglialen Morphologie. Neben ramifizierten Mikroglia lagen in den untersuchten Gehirnregionen aktivierte Mikroglia vor. Einige Mikroglia wiesen Zeichen einer Seneszenz auf und waren insbesondere in den Gehirnen von Hunden mit einer hochgradigen Aβ- bzw. Tau-Pathologie vorhanden. Zusammenfassend ist festzustellen, dass mit dieser Studie eine nähere Charakterisierung des caninen kognitiven Dysfunktionssyndroms erfolgte. Die Befunde sind von hoher translationaler Bedeutung und fördern die Etablierung des Hundes als natürliches Modelltier zur Untersuchung von Alterungsprozessen des Gehirns und für die Erforschung des initialen Stadiums der Alzheimer-Krankheit. / Dogs develop an age-associated cognitive dysfunction syndrome with several aspects resembling Alzheimer\\\'s disease. Affected animals show signs of dis-orientation in their familiar surroundings, dementia, and a disturbed circadian rhythm. The underlying neurodegenerative disease is associated with patho-logic changes in the brain including regularly deposition of β-pleated amyloid and rarely hyperphosphorylated tau accumulation. However, there have been no reports of the highly cytotoxic and modified pE3Aβ in the canine brain. Equally, altered microglial morphology has not been documented so far. For this study 24 euthanized thoroughbred dogs and mongrels of different ages were available. Five of these animals had an average age of 2.1 years and served as control group. The remaining 19 dogs were 8 to 19 years old. Accor-ding to their height and weight these dogs were divided into 3 different categories including small (≤ 10 kg), medium (11 - 25 kg) and large dogs (> 25 kg). Brains were dissected from the skulls and fixed in 4 % paraformaldehyde. Afterwards the frontal and entorhinal cortex as well as the hippocampal for-mation were isolated, vitrificated in 30 % sucrose solution and frozen to -80 °C by methylbutane. These regions were sliced into 40 µm thick sections and subsequently stained by immunohistology in order to detect deposits of Aβ8-17, pE3Aβ and hyperphosphorylated tau, respectively. Antibodies against Iba1 and TAL.1B5 were used to analyze microglial morphology and activation status. Additionally further investigations were made with the Filament Tracer of Imaris software. Stereological analysis methods served for the quantification of Aβ depositions and microglia. Disseminated Aβ plaques were detected in dogs from 9 years on. Within the examined brain regions of elderly dogs a progressive course of Aβ depositions was observed. Especially small dogs had a longer lifespan than medium and large dogs with the result that more plaques were deposited in the brains of small dogs. Elderly dogs had in common that pE3Aβ-plaques where more often located in the examined brain regions than plaques containing Aβ8-17. Minor parenchymal and meningeal vessels seemed to be susceptible especially to pE3Aβ depositions. The amount of vessel-associated Aβ8-17 and pE3Aβ in the entorhinal cortex of small dogs was almost equal. Within the entorhinal cortex of medium and large dogs the amount of vessel-associated Aβ8-17 predominated. The ventral hippocampus of small dogs showed significantly more vessel-associated Aβ8-17 than pE3Aβ depositions. Hyperphosphorylated tau was present in the hippocampal formations of 3 dogs with an age of 11 and 15 years, respectively. The degree of severity varied with the result that only one dog showed a high-grade pathology with development of NFTs and neuritic plaques. Accompanied by age and associated protein pathology altered microglial morphology was detected. Alongside with ramified microglia, activated cells were identified in the examined brain regions. Several microglia showed signs of senescence and were present in the brains of dogs with severe Aβ and tau pathology. Summarizing, this study facilitated a further characterization of the canine cognitive dysfunction syndrome. The results are of highly translational importance and encourage the establishment of the dog as a natural animal model for studying age-associated processes and the initial stage of Alzheimer’s disease.

Objective: To study awareness of cognitive dysfunction in patients with very mild Alzheimer’s disease (AD) and subjects with mild cognitive impairment (MCI). Methods: A complaint interview covering 13 cognitive domains was administered to 82 AD and 79 MCI patients and their caregivers. The patient groups were comparable according to age and education, and Mini Mental State Examination (MMSE) scores were ≥24 in all cases. The discrepancy between the patients’ and caregivers’ estimations of impairments was taken as a measure of anosognosia. Results: Self-reports of cognitive difficulties were comparable for AD and MCI patients. However, while in comparison to caregivers MCI patients reported significantly more cognitive impairment (p < 0.05), AD patients complained significantly less cognitive dysfunctions (p < 0.001). Conclusions: While most MCI patients tend to overestimate cognitive deficits when compared to their caregiver’s assessment, AD patients in early stages of disease underestimate cognitive dysfunctions. Anosognosia can thus be regarded as a characteristic symptom at a stage of very mild AD (MMSE ≥24) but not MCI. Accordingly, medical history even in mildly affected patients should always include information from both patient and caregiver. / Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.

INTRODUÇÃO: O comprometimento cognitivo observado na lesão axonial difusa (LAD) é considerado uma das mais debilitantes sequelas neurológicas nesta população. A estimulação magnética transcraniana (EMT), uma técnica de estimulação encefálica não-invasiva, tem sido utilizada com sucesso no tratamento de doenças neuropsiquiátricas. Os resultados pouco satisfatórios dos tratamentos convencionais dos distúrbios cognitivos vistos no traumatismo cranioencefálico (TCE) motivaram a investigação por novas estratégias terapêuticas, dentre elas a EMT. Entretanto, até o presente momento, não há estudos Sham-controlados investigando os efeitos cognitivos induzidos pela EMT nessa população. Assim, o presente estudo avaliou a segurança, tolerabilidade e eficácia da EMT na reabilitação cognitiva de pacientes com LAD crônica. MÉTODOS: Trata-se de um ensaio clínico prospectivo aleatorizado, duplamente encoberto, que incluiu 37 participantes com o diagnóstico de LAD crônica, em dois grupos de intervenção: Ativo e Sham. A EMT repetitiva (EMTr) de alta frequência (10 Hz) foi aplicada no córtex pré-frontal dorsolateral (CPFDL) esquerdo em um total de 10 sessões, com intensidade de 110% do limiar motor de repouso. Todos os participantes realizaram avaliação neuropsicológica (ANP), composta por sete testes neuropsicológicos [1: TMT Partes A e B; 2: Brief Visuospatial Memory Test (BVMT); 3: Hopkins Verbal Learning Test (HVLT); 4: Grooved Pegboard Test; 5: teste de Fluência Verbal semântica e fonêmica; 6: teste dos Dígitos e 7: teste dos Cinco Pontos], e avaliação da excitabilidade cortical (AEC), por meio da EMT de pulsos simples e pareados, ambas realizadas em três momentos distintos: antes da intervenção (E1 - pré-intervenção), até uma semana (E2 - pós-intervenção precoce) e 90 dias (E3 - pós-intervenção tardio) após o término da EMTr. O participante desconhecia em qual grupo de intervenção havia sido alocado, assim como o avaliador que realizou as ANPs. A medida de desfecho primário foi o escore no Trail Making Test (TMT) Parte B, um teste robusto que avalia funções executivas e atenção. RESULTADOS: Trinta participantes foram submetidos à EMTr e concluíram o seguimento, sendo 17 deles presentes no grupo Ativo e 13 no grupo Sham. Os dados demográficos pesquisados na linha de base, bem como os escores da ANP e valores aferidos na AEC, não foram diferentes entre os grupos. Com relação à performance no TMT Parte B, os tempos medianos aferidos no grupo Ativo foram 141 (100 - 209,5), 85 (67 - 274) e 161 (73 - 223) segundos nos momentos E1, E2 e E3, respectivamente, enquanto que no grupo Sham foram 97 (83 - 269), 70 (60 - 212) e 96 (59,5 - 171,5) segundos. Não houve interação tempo x grupo significativa entre as condições testadas (Ativo vs. Sham) durante os três momentos de avaliação (análise de variância ANOVA; P = 0,450), denotando não ter havido diferença no desempenho do TMT Parte B antes e após o tratamento. Consoante aos resultados do TMT Parte B, as pontuações obtidas nos outros testes incluídos na ANP não demonstraram diferenças em relação aos grupos de intervenção. Não foram observadas mudanças significativas, ou interação entre os grupos nos parâmetros avaliados na AEC. Em uma análise exploratória, observou-se alteração da inibição intracortical de intervalo curto, um dos parâmetros medidos na AEC, na linha de base do estudo em comparação com dados disponíveis na literatura em indivíduos saudáveis, sugerindo a existência de um comprometimento de circuitos corticais inibitórios nos pacientes com LAD crônica. CONCLUSÃO: Apesar de a EMT repetitiva de alta frequência no CPFDL esquerdo ter sido segura e relativamente bem tolerada, os achados deste estudo não forneceram evidências de efeito terapêutico cognitivo desta técnica em pacientes com LAD crônica. A AEC na linha de base demonstrou a presença de alteração da inibição cortical, o que amplia o conhecimento sobre os processos neurofisiológicos envolvidos neste tipo de lesão encefálica. Registro do ensaio clínico no Clinicaltrials.gov - NCT02167971 / INTRODUCTION: Cognitive impairment typically observed in diffuse axonal injury (DAI) is considered one of the main causes of disability in this population. Transcranial magnetic stimulation (TMS), a noninvasive brain stimulation technique, has been successfully used in the treatment of various neuropsychiatric disorders. The mixed results of the conventional treatments used for cognitive rehabilitation motivated the investigation of new therapeutic strategies, such as TMS. However, to the best of our knowledge, there are no sham-controlled studies addressing the cognitive effects induced by TMS in these victims. Thus, the present study aimed to evaluate the safety, tolerability and efficacy of TMS for cognitive rehabilitation in chronic DAI. METHODS: This is a prospective double-blind clinical trial that randomly included 37 participants with the diagnosis of chronic DAI in two intervention groups: Active and Sham. High frequency (10 Hz) repetitive TMS (rTMS) was applied over the left dorsolateral prefrontal cortex (DLPFC) in a total of ten sessions, at 110% intensity of the resting motor threshold. All participants underwent neuropsychological evaluation (NPE) that included 7 different neuropsychological tests [1: TMT Parts A and B; 2: Brief Visuospatial Memory Test (BVMT); 3: Hopkins Verbal Learning Test (HVLT); 4: Grooved Pegboard Test, 5: Controlled Oral Word Association Test; 6: Digit Span Test e 7: Five-Point Test], and cortical excitability assessment (CEA) with single and paired-pulse TMS, both performed at three different times: before the intervention (E1 - preintervention) , up to one week (E2 - early post-intervention) and 90 days (E3 - late post-intervention) after rTMS completion. The participant was unaware of which intervention group had been allocated, as well as the evaluator who carried out the NPEs. The primary outcome measure was the Trail Making Test (TMT) Part B, a robust test that assesses executive functions and attention. RESULTS: Thirty participants underwent rTMS and completed follow-up, 17 of them in the Active group and 13 in the Sham group. The demographic data at the baseline (E1), as well as the NPE scores and CEA values were not different between the groups. Regarding the performance in TMT Part B, the median times measured in the Active group were 141 (100 - 209.5), 85 (67 - 274) and 161 (73 - 223) seconds at evaluations E1, E2 and E3 respectively, while in the Sham group the values were 97 (83 - 269), 70 (60 - 212) and 96 (59.5 - 171.5) seconds. There was no significant interaction between the conditions tested (Active vs Sham) during the three assessments (analysis of variance ANOVA; P = 0.450), indicating that there was no difference in the performance of TMT Part B before and after treatment. As observed in the TMT Part B, no significant differences between the groups were seen in other tests included in NPE. Regarding the CEA, the parameters evaluated showed no time x group interaction. An exploratory analysis at the baseline of the study revealed alteration of short interval intracortical inhibition, one of the variables measured in CEA, when compared with data available in the literature in healthy individuals, suggesting impairment of cortical inhibitory circuits in patients with chronic LAD. CONCLUSION: rTMS was safe and well tolerated in this study. Findings did not provide evidence of therapeutic effect of 10 Hz rTMS over the left DLPFC for cognitive rehabilitation in chronic DAI. Alteration of short interval intracortical inhibition was demonstrated in this population, which expands knowledge about the neurophysiological processes involved in this type of brain injury

Le syndrome confusionnel postopératoire (SCPO) chez la personne âgée (PA) est une complication fréquente et potentiellement grave. Sa prévention constitue donc un axe de travail essentiel dans une démarche globale et multidisciplinaire d’amélioration de la prise en soin des PA en chirurgie. Après une revue de la littérature, nous avons élaboré un programme multidisciplinaire de prévention du SCPO et sa méthodologie d’évaluation. Ce programme est actuellement en cours d’évaluation grâce à une étude interventionnelle, contrôlée, randomisée en stepped wedge (étude CONFUCIUS, financée par le Programme de Recherche en Qualité Hospitalière) au sein de trois services de chirurgie (orthopédie, digestif, urologie). À ce jour, 51 patients (âge moyen = 81,6 ans et 45% de femmes) ont été inclus. Le programme de prévention sera déployé à partir de novembre 2012 dans le service de chirurgie orthopédique en collaboration avec l’équipe mobile de gériatrie de l’établissement. Préalablement, nous avons évalué les connaissances et la perception des soignants relatives au SCPO grâce à une approche quantitative et qualitative. Celles-ci sont insuffisantes, tout particulièrement concernant les signes cliniques et le diagnostic. En effet, seuls 4% des soignants connaissaient la forme hypoactive et aucun l’outil diagnostique de référence, la Confusion Assessment Method. Une banalisation du SCPO a été mise en évidence, des croyances et des représentations persistent. Cela montre qu’il est nécessaire de lutter contre les idées reçues avant d’engager toute action de prévention. Nos travaux s’inscrivent dans une démarche globale et multidisciplinaire d’amélioration de la qualité et de la sécurité des soins en chirurgie et seront poursuivis, notamment par une étude permettant de déterminer le rôle prédictif des biomarqueurs du liquide céphalo-rachidien dans la survenue de SCPO et d’une démence 12 mois après l’intervention chirurgicale chez la PA / Postoperative delirium is common in elderly and is associated with a significant increase in mortality, complications, length of hospital stay and admission in long care facility. Although several interventions have proved their effectiveness to prevent it, the Cochrane advises an assessment of multifaceted intervention using rigorous methodology bases on randomized study design. After a review of literature, a multifaceted program of delirium prevention coordinated by a mobile geriatric team (MGT) was created. This program is currently being evaluated in a randomized, controlled, interventional, stepped wedge study (the CONFUCIUS study funding by the National French Program of Hospital Quality Research) within three surgical departments (orthopedics, gastroenterology, and urology). To date, 51 patients (mean age of 81.6 years; 45% female) have been included. The program will be rolled out from November 2012 in the department of orthopedic surgery in collaboration with the hospital’s MGT. Prior to the implementation of the prevention program, the knowledge base in older postoperative delirium. Only 4% of nursing staff knew the hypoactive form and none of nursing staff knew the Confusion Assessment Method. In addition, some stereotypes persist. This work is part of a comprehensive and multidisciplinary approach to improving quality and safety in surgical care. It will be followed by a study aiming to determine the capacity of cerebrospinal fluid biomarkers in predicting the onset of POD and dementia 12 months after surgery

Cognitive and affective dysfunctions are frequent but often neglected symptoms in Parkinson’s disease (PD). We developed the screening tool Parkinson neuropsychometric dementia assessment (PANDA) with five cognitive tasks and a short depression questionnaire. Healthy subjects and patients without cognitive impairment (PD), mild cognitive disorder (PD-MCD), or dementia (PDD) were examined. The cognition part had a specificity of 91% and a sensitivity of 90% for PDD and 77% for PDD plus PD-MCD patients. The mood questionnaire also had high sensitivity and specificity. We conclude that the PANDA is an economical, easy-to-use and sensitive tool to detect neuropsychological dysfunctions in PD patients in clinical practice.